Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moOXACILLIN SODIUM (oxacillin) by Fresenius Kabi is clinical pharmacology: intravenous administration provides peak serum levels approximately 5 minutes after the injection is completed. Approved for the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. First approved in 2020.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY: Intravenous administration provides peak serum levels approximately 5 minutes after the injection is completed. Slow I.V. administration of 500 mg gives a peak serum level of 43 mcg/mL after 5 minutes with a half-life of 20 to 30 minutes. Oxacillin sodium, with normal doses,…
Worked on OXACILLIN SODIUM at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin
Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo